Brief: Tiziana Life Sciences Initiates Multi-Center Phase 2A Clinical Trial Of Intranasal Foralumab
26/09/2023 12:37
Sept 26 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES INITIATES MULTI-CENTER PHASE 2A
CLINICAL
TRIAL OF INTRANASAL FORALUMAB FOR NON-ACTIVE SECONDARY
PROGRESSIVE MULTIPLE SCLEROSIS
Source text for Eikon: ID:nGNX4BvbbT
Further company coverage: TLSA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study